The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1537
January 1, 2018
View Complete Issue         Table of Contents 2019 
Fiasp - Another Insulin Aspart Formulation for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fiasp - Another Insulin Aspart Formulation for Diabetes
January 1, 2018 (Issue: 1537)
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fiasp - Another Insulin Aspart Formulation for Diabetes
Article code: 1537c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.